Head to Head Analysis: Immunome (NASDAQ:IMNM) vs. Bicara Therapeutics (NASDAQ:BCAX)

Immunome (NASDAQ:IMNM) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Insider and Institutional Ownership

44.6% of Immunome shares are owned by institutional investors. 8.6% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Immunome and Bicara Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$10.13 million	65.32	-$106.81 million	($8.11)	-1.31
Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A

Bicara Therapeutics has lower revenue, but higher earnings than Immunome.

Profitability

This table compares Immunome and Bicara Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunome	-3,014.59%	-48.63%	-41.62%
Bicara Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Immunome and Bicara Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	0	0	7	0	3.00
Bicara Therapeutics	0	0	6	1	3.14

Immunome currently has a consensus price target of $28.83, suggesting a potential upside of 172.01%. Bicara Therapeutics has a consensus price target of $43.00, suggesting a potential upside of 199.03%. Given Bicara Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Bicara Therapeutics is more favorable than Immunome.

Summary

Bicara Therapeutics beats Immunome on 6 of the 10 factors compared between the two stocks.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

About Bicara Therapeutics

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.